Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 15 Jan 2025 |
| 79,345 Orion Corporation A shares converted into B shares | 13 Jan 2025 |
| Orion's collaboration partner Bayer submits application in China for third indication of darolutamide | 7 Jan 2025 |
| Orion and Marinus terminate agreement for ganaxolone in Europe | 30 Dec 2024 |
| Change in Orion Group Executive Management Board as of 1 June 2025 - Mikko Kemppainen appointed General Counsel | 19 Dec 2024 |
| CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 - Mikko Kemppainen appointed General Counsel | 19 Dec 2024 |